PATIENT_ID	HISTOLOGY	AGE	SEX	SMOKING_HISTORY	SMOKING_PACK_YEARS	PDL1_EXPRESSION	PRIOR_TREATMENT_OF_CYTOTOXIC_CHEMOTHERAPY	AGENT	ADMINISTRATION_OF_DRUG_WEEKS	PFS_MONTHS	EVENT_TYPE	TREATMENT_BEST_RESPONSE	DURABLE_CLINICAL_BENEFIT	MOLECULAR_SMOKING_SIGNATURE	NONSYNONYMOUS_MUTATION_BURDEN	NEOANTIGEN_BURDEN	TOTAL_EXONIC_MUTATION_BURDEN	Coded.response
luad_mskcc_2015_1	NSCLC NOS	63	Female	Former	36	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	3	8.4	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	1192	576	1732	r
luad_mskcc_2015_2	Adenocarcinoma	63	Female	Former	58	Strong(>or =50% membraneous staining)	3	Pembrolizumab (Dose 10 mg/kg)	3	14.7	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	746	610	1011	r
luad_mskcc_2015_3	Adenocarcinoma	66	Male	Current	48	Negative(<1% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	2.1	Progression-free Survival	POD	No durable benefit	Transversion High	626	446	992	nr
luad_mskcc_2015_4	Adenocarcinoma	68	Female	Never	0	Weak(1-49% membraneous staining	5	Pembrolizumab (Dose 10 mg/kg)	3	8.3	Progression-free Survival	SD	Durable clinical benefit beyond 6 months	Transversion Low	507	358	914	r
luad_mskcc_2015_6	Adenocarcinoma	60	Female	Former	21	Strong(>or =50% membraneous staining)	1	Pembrolizumab (Dose 10 mg/kg)	3	16.6	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	473	228	622	r
luad_mskcc_2015_5	Adenocarcinoma	66	Male	Former	40	Unassessable	3	Pembrolizumab (Dose 10 mg/kg)	2	14.6	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	427	300	685	r
luad_mskcc_2015_7	Adenocarcinoma	76	Female	Never	0	Negative(<1% membraneous staining)	6	Pembrolizumab (Dose 10 mg/kg)	3	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	378	209	558	nr
luad_mskcc_2015_8	Squamous Cell Carcinoma	57	Male	Former	39	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 2 mg/kg)	3	4	Censored	SD	Not reached 6 months follow-up	Transversion High	368	271	552	nr
luad_mskcc_2015_9	Adenocarcinoma	57	Male	Former	80	Strong(>or =50% membraneous staining)	3	Pembrolizumab (Dose 10 mg/kg)	3	14.5	Progression-free Survival	PR	Durable clinical benefit beyond 6 months	Transversion High	324	226	494	r
luad_mskcc_2015_12	Adenocarcinoma	64	Female	Former	52.5	Strong(>or =50% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	8.1	Progression-free Survival	SD	Durable clinical benefit beyond 6 months	Transversion High	302	114	426	r
luad_mskcc_2015_10	Adenocarcinoma	64	Female	Current	25	Weak(1-49% membraneous staining	0	Pembrolizumab (Dose 10 mg/kg)	3	12.6	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	296	191	450	r
luad_mskcc_2015_13	Adenocarcinoma	56	Male	Former	37.5	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	2	1.8	Progression-free Survival	POD	No durable benefit	Transversion High	292	90	396	nr
luad_mskcc_2015_11	Adenocarcinoma	65	Female	Current	25	Strong(>or =50% membraneous staining)	1	Pembrolizumab (Dose 2 mg/kg)	3	4.2	Censored	PR	Not reached 6 months follow-up	Transversion High	290	208	441	r
luad_mskcc_2015_15	Adenocarcinoma	59	Male	Former	34	Strong(>or =50% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	8.4	Censored	SD	Durable clinical benefit beyond 6 months	Transversion High	244	148	341	r
luad_mskcc_2015_18	Adenocarcinoma	61	Female	Current	60	Strong(>or =50% membraneous staining)	6	Pembrolizumab (Dose 10 mg/kg)	3	9.8	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	228	215	326	r
luad_mskcc_2015_14	Adenocarcinoma	57	Female	Former	25	Strong(>or =50% membraneous staining)	1	Pembrolizumab (Dose 2 mg/kg)	3	4.4	Censored	PR	Not reached 6 months follow-up	Transversion High	223	111	342	r
luad_mskcc_2015_20	Adenocarcinoma	78	Female	Former	60	Strong(>or =50% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	10.4	Censored	PR	Durable clinical benefit beyond 6 months	Transversion Low	201	135	305	r
luad_mskcc_2015_19	Squamous Cell Carcinoma	68	Male	Never	0	Unassessable	2	Pembrolizumab (Dose 10 mg/kg)	3	27.3	Censored	PR	Durable clinical benefit beyond 6 months	Transversion Low	198	80	316	r
luad_mskcc_2015_16	Adenocarcinoma	60	Male	Never	0	Negative(<1% membraneous staining)	5	Pembrolizumab (Dose 10 mg/kg)	2	3.3	Progression-free Survival	POD	No durable benefit	Transversion Low	190	118	341	nr
luad_mskcc_2015_21	Adenocarcinoma	59	Male	Current	15	Weak(1-49% membraneous staining	0	Pembrolizumab (Dose 10 mg/kg)	2	8.3	Progression-free Survival	SD	Durable clinical benefit beyond 6 months	Transversion High	185	100	292	r
luad_mskcc_2015_17	Squamous Cell Carcinoma	51	Female	Former	2.5	Negative(<1% membraneous staining)	4	Pembrolizumab (Dose 10 mg/kg)	2	3.4	Progression-free Survival	POD	No durable benefit	Transversion Low	184	50	328	nr
luad_mskcc_2015_23	Squamous Cell Carcinoma	59	Male	Current	45	Negative(<1% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	2	1.9	Progression-free Survival	POD	No durable benefit	Transversion High	170	51	255	nr
luad_mskcc_2015_22	Adenocarcinoma	73	Female	Former	43.75	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	2	6.5	Progression-free Survival	SD	No durable benefit	Transversion Low	148	99	261	r
luad_mskcc_2015_24	Adenocarcinoma	50	Male	Never	0	Weak(1-49% membraneous staining	6	Pembrolizumab (Dose 10 mg/kg)	2	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	134	99	209	nr
luad_mskcc_2015_26	Adenocarcinoma	49	Male	Never	0	Strong(>or =50% membraneous staining)	2	Pembrolizumab (Dose 10 mg/kg)	3	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	127	58	190	nr
luad_mskcc_2015_25	Adenocarcinoma	63	Male	Former	73.5	Weak(1-49% membraneous staining	2	Pembrolizumab (Dose 2 mg/kg)	3	1.4	Progression-free Survival	POD	No durable benefit	Transversion Low	122	83	199	nr
luad_mskcc_2015_28	Adenocarcinoma	62	Female	Former	6	Weak(1-49% membraneous staining	2	Pembrolizumab (Dose 2 mg/kg)	3	3.5	Progression-free Survival	SD	No durable benefit	Transversion Low	109	74	145	nr
luad_mskcc_2015_27	Adenocarcinoma	71	Male	Former	20	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	3	2.1	Progression-free Survival	POD	No durable benefit	Transversion Low	106	112	167	nr
luad_mskcc_2015_29	Adenocarcinoma	56	Female	Former	8	Weak(1-49% membraneous staining	0	Pembrolizumab (Dose 10 mg/kg)	2	6.3	Progression-free Survival	SD	No durable benefit	Transversion Low	79	87	140	r
luad_mskcc_2015_30	Adenocarcinoma	80	Male	Former	56	Negative(<1% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	8.3	Progression-free Survival	PR	Durable clinical benefit beyond 6 months	Transversion Low	56	30	94	r
luad_mskcc_2015_32	Adenocarcinoma	41	Female	Current	2.25	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	3	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	35	18	85	nr
luad_mskcc_2015_33	Adenocarcinoma	64	Male	Former	10	Weak(1-49% membraneous staining	2	Pembrolizumab (Dose 10 mg/kg)	2	1.8	Progression-free Survival	POD	No durable benefit	Transversion Low	34	27	80	nr
luad_mskcc_2015_31	Adenocarcinoma	71	Female	Former	0.5	Unassessable	1	Pembrolizumab (Dose 10 mg/kg)	3	4.1	Progression-free Survival	SD	No durable benefit	Transversion Low	22	11	88	nr
luad_mskcc_2015_34	Adenocarcinoma	57	Female	Former	3.15	Unassessable	1	Pembrolizumab (Dose 10 mg/kg)	3	6.3	Progression-free Survival	SD	No durable benefit	Transversion Low	11	8	45	r